Blavatnik Startups | Yale Ventures

Startups

To date the Blavatnik Fund has launched 28 startups. The below list highlights the currently active ventures and ventures that have been acquired. Those that are either raising a round or seeking leadership are denoted with a *.

Alphina Therapeutics

Oncology therapies targeting cancer metabolic pathways

Fundraising status: Raised Series A (2022)

Clinical Stage: Preclinical

CEO: Mark Cockett

Faculty Founder: Ranjit Bindra

C8 Sciences

Combining Neuroscience and Video Games to Improve Mental and Emotional Health

Fundraising status: Angel Funding

Stage: Commercial, engaging FDA for clinical indication

CEO: Tim Kish

Faculty Founder: Bruce Wexler

Curatix*

Potentiators of Anti-Microbial Susceptibility (PAMS) - Promise for treating drug-resistant fungal pathogens

Fundraising status: SBIR (Awarded 2023)

Stage: Preclinical

CEO: Seeking CEO

Faculty Founder: Choukri Ben Mamoun

Cytosolix

Targeting cancer cells through acidity

Fundraising status: Raised Seed Round (2023)

Clinical Stage: Preclinical

CEO: Colin Foster

Faculty Founder: John Deacon

Gennao

Targeted nucleic acid therapeutics

Fundraising status: Raised Series B (2022)

Clinical Stage: Preclinical

CEO: Chris Duke

Faculty Founder: Peter Glazer

from ENSIGHT Inno Summit 2024 Presentation

ENSIGHT-AI*

Identifying structural heart disorders from widely available electrocardiograms and wearables

Fundraising status: Raising Seed

Stage: IND Filing

CEO:

Faculty Founder: Rohan Khera

Entelion*

Enzyme Replacement Therapy for the Treatment of Autoimmune Disease

Fundraising status: Currently Raising Series A

Stage: Preclinical

CEO:

Faculty Founder: Demetrios Braddock

EvolveImmune

Overcome CD8 T cell exhaustion in the tumor microenvironment

Fundraising status: Raised Series A (2023)

Clinical Stage: Preclinical

CEO: Stephen Bloch

Faculty Founders: Sidi Chen

IntronX*

Potent small molecule inhibitors of fungal RNA metabolism

Fundraising status: Raising Seed Round

Stage: Preclinical

CEO: Seeking CEO

Faculty Founder: Anna Pyle

MagicTime Medicine

New Paradigm of Immune Gene Therapy

Fundraising status: Raised Seed (2024)

Clinical Stage: Preclinical

CEO:

Faculty Founder: Sidi Chen

Manifest Technologies*

De-risk CNS drug R&D through computational neuroimaging platform

Fundraising status: Raised Seed (2023), Raising Series A

Stage: Commercial

CEO: Markus Helmer

Faculty Founder: Alan Anticevic

Pangolin Therapeutics*

Targeting toxic intrinsically disordered proteins

Fundraising status: Currently raising Series A

Clinical Stage: Preclinical

CEO: Susan Froshauer

Faculty Founders: Andrew Miranker

Playbl

Harness the power of play to enable healthier and better lives for adolescents

Fundraising status: Commercial revenue

Stage: Commercial

CEO: Seeking CEO

Faculty Founder: Lynn Fiellin

Pure Marrow*

Clinically relevant stem cell doses

Fundraising status: Currently raising Series A

Clinical Stage: Preclinical

CEO: Paul Tessier

Faculty Founders: Elliott Brown

RIGImmune

Harnessing the Innate Immune System

Fundraising status: Raised Seed Round (2022)

Clinical Stage: Preclinical

CEO: Susan Sobolov

Faculty Founders: Anna Pyle & Akiko Iwasaki

Simcha Therapeutics

Cytokines as therapeutics

Fundraising status: Raised Series B (2022)

Clinical Stage: Phase 1/2

CEO: Sanuj Ravindran

Faculty Founders: Aaron Ring

Fig 2. Proc Natl Acad Sci U S A . 2021 Feb 16;118(7)

StraDEFY*

Bioadhesive nanoparticle platform

Fundraising status: Currently raising Series A

Clinical Stage: Preclinical

CEO: Seeking CEO

Faculty Founders: Mark Saltzman & Michael Girardi

TargetSite Therapeutics

mRNA-targeted Therapeutics Platform Company

Fundraising status: Sponsored research

Stage: Preclinical

CEO: Adi Gottumukkala

Faculty Founder: Jeff Bender

Virtus Therapeutics

Treating PKAN (Pantothenate Kinase-Associated Neurodegeneration)

Fundraising status: SBIR (Awarded 2023)

Stage: Preclinical

CEO: Seeking CEO

Faculty Founder: Choukri Ben Mamoun